Inna Gaisler-Salomon

Prof. Inna Gaisler-Salomon

University of Haifa, Haifa, Israel
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Neurobiology of Aging
Verified
Journal Article
Closed access
Inna Gaisler-SalomonInna Gaisler-Salomon
Inna Gaisler-Salomon
EKEfrat Kravitz
Efrat Kravitz
YFYulia Feiler
Yulia Feiler
MSMichal Safran
Michal Safran
ABAnat Biegon
Anat Biegon
GRGideon Rechavi
Gideon Rechavi

1 January 2017 in Behavioural Brain Research
Verified
Journal Article
Closed access
SLSharon S. Lander
Sharon S. Lander
DLDonna Linder-Shacham
Donna Linder-Shacham
Inna Gaisler-SalomonInna Gaisler-Salomon
Inna Gaisler-Salomon

14 October 2021 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
JMJohanna Merlin
Johanna Merlin
SIStoyan Ivanov
Stoyan Ivanov
ADAdélie Dumont
Adélie Dumont
ASAlexey Sergushichev
Alexey Sergushichev
JGJulie Gall
Julie Gall
LYLaurent Yvan-Charvet
Laurent Yvan-Charvet


10 June 2009 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
Inna Gaisler-SalomonInna Gaisler-Salomon
Inna Gaisler-Salomon
GMGretchen M Miller
Gretchen M Miller
NCNao Chuhma
Nao Chuhma
SLSooyeon Lee
Sooyeon Lee
HZHong Zhang
Hong Zhang
SRStephen Rayport
Stephen Rayport
Dysregulated glutamatergic neurotransmission has been strongly implicated in the pathophysiology of schizophrenia (SCZ). Recently, presynaptic modulation of glutamate transmission has been shown to have therapeutic promise. We asked whether genetic knockdown of glutaminase (gene GLS1) to reduce glutamatergic transmission presynaptically by slowing the recycling of glutamine to glutamate, would produce a phenotype relevant to SCZ and its treatment. GLS1 heterozygous (GLS1 het) mice showed about a 50% global reduction in glutaminase activity, and a modest reduction in glutamate levels in brain regions relevant to SCZ pathophysiology, but displayed neither general behavioral abnormalities nor SCZ-associated phenotypes. Functional imaging, measuring regional cerebral blood volume, showed hippocampal hypometabolism mainly in the CA1 subregion and subiculum, the inverse of recent clinical imaging findings in prodromal and SCZ patients. GLS1 het mice were less sensitive to the behavioral stimulating effects of amphetamine, showed a reduction in amphetamine-induced striatal dopamine release and in ketamine-induced frontal cortical activation, suggesting that GLS1 het mice are resistant to the effects of these pro-psychotic challenges. Moreover, GLS1 het mice showed clozapine-like potentiation of latent inhibition, suggesting that reduction in glutaminase has antipsychotic-like properties. These observations provide further support for the pivotal role of altered glutamatergic synaptic transmission in the pathophysiology of SCZ, and suggest that presynaptic modulation of the glutamine–glutamate pathway through glutaminase inhibition may provide a new direction for the pharmacotherapy of SCZ.